Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04908865 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Belimumab
DRUG: Standard therapy

Sponsor

GlaxoSmithKline